Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Accumulated Depreciation & Amortization (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Accumulated Depreciation & Amortization data on record, last reported at $169608.0 in Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $169608.0; the TTM value through Sep 2025 reached $169608.0, changed N/A, while the annual FY2024 figure was $123357.0, 32.93% up from the prior year.
  • Accumulated Depreciation & Amortization reached $169608.0 in Q3 2025 per GANX's latest filing, up from $159709.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $169608.0 in Q3 2025 and bottomed at $3403.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $73490.9, with a median of $71933.0 recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 27.05% in 2021, then surged 871.05% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $15484.0 in 2021, then surged by 244.41% to $53329.0 in 2022, then surged by 74.01% to $92797.0 in 2023, then skyrocketed by 32.93% to $123357.0 in 2024, then surged by 37.49% to $169608.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $169608.0 in Q3 2025, $159709.0 in Q2 2025, and $136778.0 in Q1 2025.